Showing results (151-160 of 279) with videos related to
Sort By:
Pageof 28
Kidney International Reports|November 17, 2017
Prognostic Enrichment Design in Clinical Trials for Autosomal Dominant Polycystic Kidney Disease: The TEMPO 3:4 Clinical TrialMaria V Irazabal, Jaime D Blais, Ronald D Perrone, et al.Clinical Journal of the American Society of Nephrology : CJASN|January 23, 2016
Automated Segmentation of Kidneys from MR Images in Patients with Autosomal Dominant Polycystic Kidney DiseaseYoungwoo Kim, Yinghui Ge, Cheng Tao, et al.Clinical Journal of the American Society of Nephrology : CJASN|May 16, 2019
Growth Pattern of Kidney Cyst Number and Volume in Autosomal Dominant Polycystic Kidney DiseaseKyongtae T Bae, Wen Zhou, Chengli Shen, et al.American Journal of Hypertension|July 27, 2013
Night blood pressure responses to atenolol and hydrochlorothiazide in black and white patients with essential hypertensionArlene B Chapman, George Cotsonis, Vishal Parekh, et al.Clinical Journal of the American Society of Nephrology : CJASN|February 13, 2026
Relationship between Total Kidney Volume and Estimated Glomerular Filtration Rate in Autosomal Dominant Polycystic Kidney DiseaseAlan S L Yu, Chelsie Parker, Lilian Golzarri-Arroyo, et al.Journal of the American Society of Nephrology : JASN|February 3, 2006
Comparison of methods for determining renal function decline in early autosomal dominant polycystic kidney disease: the consortium of radiologic imaging studies of polycystic kidney disease cohortAndrew D Rule, Vicente E Torres, Arlene B Chapman, et al.Clinical Journal of the American Society of Nephrology : CJASN|March 23, 2013
Segmentation of individual renal cysts from MR images in patients with autosomal dominant polycystic kidney diseaseKyungsoo Bae, Bumwoo Park, Hongliang Sun, et al.BMC Nephrology|April 19, 2018
Assessing known chronic kidney disease associated genetic variants in Saudi Arabian populationsCyril Cyrus, Samir Al-Mueilo, Chittibabu Vatte, et al.Kidney International|March 23, 2019
Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney diseaseRon T Gansevoort, Maatje D A van Gastel, Arlene B Chapman, et al.American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|February 22, 2011
Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 StudyVicente E Torres, Esther Meijer, Kyongtae T Bae, et al.Pageof 28